Vistagen Therapeutics (VTGN) Return on Sales (2017 - 2025)
Historic Return on Sales for Vistagen Therapeutics (VTGN) over the last 12 years, with Q4 2025 value amounting to 62.37%.
- Vistagen Therapeutics' Return on Sales fell 21600.0% to 62.37% in Q4 2025 from the same period last year, while for Dec 2025 it was 84.87%, marking a year-over-year decrease of 137300.0%. This contributed to the annual value of 105.8% for FY2025, which is 782000.0% down from last year.
- According to the latest figures from Q4 2025, Vistagen Therapeutics' Return on Sales is 62.37%, which was down 21600.0% from 75.26% recorded in Q3 2025.
- Over the past 5 years, Vistagen Therapeutics' Return on Sales peaked at 909.0% during Q1 2025, and registered a low of 427.9% during Q1 2022.
- Moreover, its 5-year median value for Return on Sales was 56.14% (2024), whereas its average is 20.77%.
- Its Return on Sales has fluctuated over the past 5 years, first crashed by -4138500bps in 2022, then soared by 9670500bps in 2025.
- Over the past 5 years, Vistagen Therapeutics' Return on Sales (Quarter) stood at 29.42% in 2021, then plummeted by -84bps to 54.23% in 2022, then skyrocketed by 72bps to 15.45% in 2023, then tumbled by -290bps to 60.21% in 2024, then fell by -4bps to 62.37% in 2025.
- Its last three reported values are 62.37% in Q4 2025, 75.26% for Q3 2025, and 61.86% during Q2 2025.